$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-031/24
출원번호 US-0123118 (1987-11-20)
우선권정보 IT-0020737 (1986-06-10); IT-0019221 (1987-01-30)
발명자 / 주소
  • Chiesi Paolo (Parma ITX)
출원인 / 주소
  • Chiesi Farmaceutici S.p.A. (Parma ITX 03)
인용정보 피인용 횟수 : 66  인용 특허 : 1

초록

Pharmaceutical compositions for the treatment of Parkinson\s disease and neurologic syndromes connected with it, containing as the active principle Levodopa methyl ester optionally combined with other active principles selected from dopaminergi, anticholinergic, antidepressive drugs, carboxylase and

대표청구항

A pharmaceutical composition for oral and sublingual use which contains per unit dose 100 to 300 mg of levodopa methyl ester (LDME) as one active ingredient and a member selected from the group consisting of benserazide, carbidopa and deprenyl in the ratio respectively of 2:1 to 5:1; 4:1 to 20:1, an

이 특허에 인용된 특허 (1)

  1. Repta A. J. (Lawrence KS), Rectally absorbable form of L-dopa.

이 특허를 인용한 특허 (66)

  1. Chorev, Michael; Goren, Tamar; Herzig, Yacov; Sterling, Jeffrey; Weinstock-Rosin, Marta; Youdim, Moussa B.H., Aminoindan derivatives.
  2. Chorev,Michael; Goren,Tamar; Herzig,Yacov; Sterling,Jeffrey; Weinstock Rosin,Marta; Youdim,Moussa B. H., Aminoindan derivatives.
  3. Michael Chorev IL; Tamar Goren IL; Yacov Herzig IL; Jeffrey Sterling IL; Marta Weinstock-Rosin IL; Moussa B. H. Youdim IL, Aminoindan derivatives.
  4. Xiang,Jia Ning; Gallop,Mark A.; Cundy,Kenneth C.; Li,Jianhua; Xu,Feng; Zhou,Cindy X.; Bhat,Laxminarayan, Carbidopa prodrugs and derivatives, and compositions and uses thereof.
  5. Xiang, Jia-Ning; Zhou, Cindy X.; Yao, Fenmei; Nguyen, Mark Q., Catechol protected levodopa diester prodrugs, compositions, and methods of use.
  6. Xiang, Jia-Ning; Zhou, Cindy X.; Yao, Fenmei; Nguyen, Mark Q., Catechol protected levodopa diester prodrugs, compositions, and methods of use.
  7. Di Paolo, Thérèse, Combined therapy for the treatment of parkinson's disease.
  8. McLellan, Alexander; Greenway, Frank, Composition and method for inhibition of nerve transmission.
  9. Yacoby-Zeevi, Oron; Nemas, Mara, Compositions comprising apomorphine and organic acids and uses thereof.
  10. Yacoby-Zeevi, Oron; Nemas, Mara, Compositions comprising apomorphine and organic acids and uses thereof.
  11. McLellan, Alexander; Greenway, Frank, Compositions comprising terpene compounds for treating negative sensory phenomena.
  12. Sklarz, Benjamin; Cohen, Sasson; Speiser, Tzipora; Nachman, Rachel, Compositions containing and methods of using N-acyl-1H-aminoindenes.
  13. Yacoby-Zeevi, Oron; Nemas, Mara, Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same.
  14. Yacoby-Zeevi, Oron; Nemas, Mara, Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same.
  15. Yacoby-Zeevi, Oron; Nemas, Mara, Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same.
  16. Yacoby-Zeevi, Oron; Nemas, Mara, Continuous administration of dopa decarboxylase inhibitors and compositions for same.
  17. Yacoby-Zeevi, Oron; Nemas, Mara, Continuous administration of dopa decarboxylase inhibitors and compositions for same.
  18. Yacoby-Zeevi, Oron; Nemas, Mara, Continuous administration of dopa decarboxylase inhibitors and compositions for same.
  19. Yacoby-Zeevi, Oron; Nemas, Mara, Continuous administration of dopa decarboxylase inhibitors and compositions for same.
  20. Yacoby-Zeevi, Oron; Nemas, Mara, Continuous administration of dopa decarboxylase inhibitors and compositions for same.
  21. Yacoby-Zeevi, Oron; Nemas, Mara, Continuous administration of dopa decarboxylase inhibitors and compositions for same.
  22. Dempski Robert E. (Dresher PA) Scholtz Edward C. (King of Prussia PA) Nibbelink Donald W. (Lansdale PA) Reines Scott A. (New Hope PA), Controlled release combination of carbidopa/levodopa.
  23. Hsu, Ann; Kou, Jim; Alani, Laman, Controlled release formulations of levodopa and uses thereof.
  24. Yacoby-Zeevi, Oron, DOPA decarboxylase inhibitor compositions.
  25. Galit Levin IL, Dispersible compositions containing L-DOPA ethyl ester.
  26. Levin, Galit; Tsipori, Omer, Dispersible compositions containing L-DOPA ethyl ester.
  27. Yacoby-Zeevi, Oron, Dopa decarboxylase inhibitor compositions.
  28. Youdim Moussa B. H. (Haifa ILX) Finberg John P. M. (Tivon ILX) Levy Ruth (Tel-Aviv ILX) Sterling Jeffrey (Jerusalem ILX) Lerner David (Jerusalem ILX) Yellin Haim (Ramat-Gan ILX) Veinberg Alex (Rehovo, Esylate and sulfate salts of R(+)-N-propargyl-1-aminoindan.
  29. Milman Isaac (Maale Adumim ILX) Veinberg Alexander (Rehovot ILX) Atlas Daphne (Neve Granot ILX) Melamed Eldad (Mevasserett Zion ILX), L-DOPA ethyl ester to treat Parkinson\s disease.
  30. Xiang, Jia-Ning; Zhou, Cindy X.; Yao, Fenmei; Nguyen, Mark Q., Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use.
  31. Xiang, Jia-Ning; Zhou, Cindy X.; Yao, Fenmei; Nguyen, Mark Q., Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use.
  32. Karaborni, Sami; Leung, Manshiu; Mao, Chen; Thalladi, Venkat, Levodopa prodrug mesylate hydrate.
  33. Karaborni, Sami; Leung, Manshiu; Mao, Chen; Thalladi, Venkat R., Levodopa prodrug mesylate hydrate.
  34. Xiang, Jia Ning; Dai, Xuedong; Zhou, Cindy X.; Li, Jianhua; Nguyen, Mark Q., Levodopa prodrug mesylate, compositions thereof, and uses thereof.
  35. Xiang, Jia-Ning; Dai, Xuedong; Zhou, Cindy X.; Li, Jianhua; Nguyen, Mark Q., Levodopa prodrug mesylate, compositions thereof, and uses thereof.
  36. Xiang, Jia-Ning; Dai, Xuedong; Zhou, Cindy X.; Li, Jianhua; Nguyen, Mark Q., Levodopa prodrug mesylate, compositions thereof, and uses thereof.
  37. Xiang, Jia-Ning; Dai, Xuedong; Zhou, Cindy X.; Li, Jianhua; Nguyen, Mark Q., Levodopa prodrug mesylate, compositions thereof, and uses thereof.
  38. Xiang, Jia Ning; Gallop, Mark A.; Zhou, Cindy X.; Nguyen, Mark; Dai, Xuedong; Li, Jianhua; Cundy, Kenneth C.; Jumbe, Nelson L., Levodopa prodrugs, and compositions and uses thereof.
  39. Xiang, Jia-Ning; Gallop, Mark A.; Zhou, Cindy X.; Nguyen, Mark; Dai, Xuedong; Li, Jianhua; Cundy, Kenneth C.; Jumbe, Nelson L., Levodopa prodrugs, and compositions and uses thereof.
  40. Xiang, Jia-Ning; Gallop, Mark A.; Zhou, Cindy X.; Nguyen, Mark; Dai, Xuedong; Li, Jianhua; Cundy, Kenneth C.; Jumbe, Nelson L., Levodopa prodrugs, and compositions and uses thereof.
  41. Xiang,Jia Ning; Gallop,Mark A.; Zhou,Cindy X.; Nguyen,Mark; Dai,Xuedong; Li,Jianhua; Cundy,Kenneth C., Levodopa prodrugs, and compositions and uses thereof.
  42. Xiang,Jia Ning; Gallop,Mark A.; Zhou,Cindy X.; Nguyen,Mark; Dai,Xuedong; Li,Jianhua; Cundy,Kenneth C.; Jumbe,Nelson L., Levodopa prodrugs, and compositions and uses thereof.
  43. Mark G. Resnick, Method for treating wounds, burns and dermatological damage by administering selegiline or desmethylselegiline.
  44. Youdim Moussa B. H. (Haifa ILX) Finberg John P. M. (Tivon ILX) Levy Ruth (Tel-Aviv ILX) Yellin Haim (Ramat-Gan ILX), Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds.
  45. Resnick,Mark G., Methods for preventing photodamaged skin by administering selegiline or desmethylselegiline.
  46. Resnick, Mark G., Methods for treating photodamaged skin by administering selegiline or desmethylselegiline.
  47. Raillard, Stephen P.; Mann, Adam; Manthati, Suresh K.; Scheuerman, Randall A.; Estrada, Tono; Nguyen, Mark Q.; Zhou, Cindy X, Methods of synthesizing a levodopa ester prodrug.
  48. Hsu, Ann; Dong, Liang C.; Ding, Amy; Gupta, Suneel, Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof.
  49. Remenar, Julius; Almarsson, Orn; Meehan, Jr., Anthony J.; Zhang, Zhong, Pharmaceutical compositions and method of using levodopa and carbidopa.
  50. Mao, Chen; Pargaonkar, Nikhil; Maurer, Laura E.; Ma, Sarina Grace Harris, Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use.
  51. Heller, Adam; Heller, Ephraim; Westerberg, Karl Göran; Spiridigliozzi, John, Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use.
  52. Lidor Ramy,ILX ; Bahar Eliezer,ILX ; Frenkel Anton,ILX, Process for manufacturing of L-DOPA ethyl ester.
  53. Piryatinsky, Victor; Cohen, Bronka; Lerner, David; Pinkert, Dalia; Miskolczi, Istvan; Herzig, Yaacov; Gottlieb, Hugo, Propargylated aminoindans, processes for preparation, and uses thereof.
  54. Piryatinsky, Victor; Cohen, Bronka; Lerner, David; Pinkert, Dalia; Miskolczi, Istvan; Herzig, Yaacov; Gottlieb, Hugo; Weinstock-Rosin, Marta, Propargylated aminoindans, processes for preparation, and uses thereof.
  55. Youdim Moussa B.H.,ILX ; Finberg John P.M.,ILX ; Levy Ruth,ILX ; Yellin Haim,ILX, R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia.
  56. DiSanto Anthony R., Sublingual and buccal administration of selegiline for treating certain selegiline-responsive diseases and conditions.
  57. Mantelle Juan ; Houze David, Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures.
  58. Mantelle, Juan; Houze, David, Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures.
  59. Youdim Moussa B. H.,ILX ; Finberg John P. M.,ILX ; Levy Ruth,ILX ; Sterling Jeffrey,ILX ; Lerner David,ILX ; Yellin Haim,ILX ; Veinberg Alex,ILX, Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof.
  60. Youdim Moussa B. H.,ILX ; Finberg John P. M.,ILX ; Levy Ruth,ILX ; Sterling Jeffrey,ILX ; Lerner David,ILX ; Yellin Haim,ILX ; Veinberg Alex,ILX, Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof.
  61. Youdim, Moussa B. H.; Finberg, John P. M.; Levy, Ruth; Sterling, Jeffrey, Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof.
  62. Youdim, Moussa B. H.; Finberg, John P. M.; Levy, Ruth; Sterling, Jeffrey; Lerner, David; Yellin, Haim; Veinberg, Alex, Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof.
  63. Weinstock-Rosin, Marta; Shoham, Shai, Use of low-dose ladostigil for neuroprotection.
  64. Youdim Moussa B. H. (Haifa ILX) Finberg John P. M. (Tivon ILX) Levy Ruth (Tel-Aviv ILX) Sterling Jeffrey (Jerusalem ILX) Lerner David (Jerusalem ILX) Berger-Paskin Tirtsah (Raanana ILX) Yellin Haim (, Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for the treatment of depression.
  65. Kang, Un Jung, Vesicular monoamine transporter gene therapy in Parkinson's disease.
  66. Kang,Un Jung, Vesicular monoamine transporter gene therapy in parkinson's disease.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로